1. Establishment and characterization of mouse metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma organoids.
- Author
-
Kim S, Jeong N, Park J, Noh H, Lee JO, Yu SJ, and Ku JL
- Subjects
- Animals, Mice, Phenylurea Compounds pharmacology, Disease Models, Animal, Fatty Liver metabolism, Fatty Liver pathology, Diet, High-Fat adverse effects, Drug Resistance, Neoplasm, Male, Humans, Mice, Inbred C57BL, Epithelial-Mesenchymal Transition, Liver metabolism, Liver pathology, Carcinoma, Hepatocellular metabolism, Carcinoma, Hepatocellular pathology, Organoids metabolism, Organoids pathology, Liver Neoplasms metabolism, Liver Neoplasms pathology, Quinolines pharmacology
- Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is a form of chronic liver inflammation associated with metabolic syndrome, such as obesity and a major cause of hepatocellular carcinoma (HCC). Multi-biotics, a soymilk fermented with lactic acid bacteria, are known to alleviate obesity by lowering lipid profile. This study aimed to establish and characterize mouse organoids derived from MASH-related HCC models to evaluate drug responses, particularly focusing on Lenvatinib resistance. Organoids were developed using mouse liver tissues subjected to a choline-deficient L-amino acid-defined high-fat diet (CDAHFD) to mimic MASH-related HCC. The study evaluated the effect of multi-biotics, a fermented product, on tumor regression and drug sensitivity. While multi-biotics did not reduce tumor burden, they enhanced the response to Lenvatinib. Additionally, repeated treatment with Lenvatinib led to the development of drug-resistant organoids. Transcriptomic analysis of these resistant organoids identified key pathways related to KRAS signaling, inflammation, and epithelial-mesenchymal transition (EMT), revealing potential targets for overcoming Lenvatinib resistance. This study provides valuable insights into MASH-related HCC progression and drug resistance, offering a model for further therapeutic research., Competing Interests: Declarations Competing interests The authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF